Knight Therapeutics (TSE:GUD) Sets New 1-Year High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD)’s stock price hit a new 52-week high on Tuesday. The stock traded as high as C$10.41 and last traded at C$10.41, with a volume of 22311 shares changing hands. The stock had previously closed at C$10.27.

Knight Therapeutics Price Performance

The company has a debt-to-equity ratio of 4.29, a quick ratio of 1.79 and a current ratio of 2.28. The stock has a market capitalization of C$1.02 billion, a price-to-earnings ratio of 69.13, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.29. The business’s 50 day simple moving average is C$9.79 and its 200-day simple moving average is C$8.81.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) earnings per share (EPS) for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%.The business had revenue of C$143.97 million for the quarter. Research analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.